(RTTNews) - The U.S. Food and Drug Administration has extended by three months the target action date of its priority review of the supplemental Biologics License Application or sBLA for Dupixent ...

If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children Atopic dermatitis is a chronic type ...

(RTTNews) - Sanofi (SNY) announced the FDA has accepted for Priority Review the supplemental Biologics License Application for Dupixent to treat children aged 1 to 11 years with eosinophilic ...

On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

Priority Review granted based on positive results from two Phase 3 trials If approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more ...

Paris and Tarrytown, N.Y. September 26, 2023. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® ...

Regeneron and Sanofi have reached another milestone as they look to add to their megablockbuster immunology drug Dupixent a new U.S. indication for uncontrolled chronic obstructive pulmonary disease ...

Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...